Compare Noble Corporation plc (NE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Regeneron Pharmaceuticals Inc — how do they compare? Noble Corporation plc trades at $44.25 (market cap $6.51B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 12.8× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.91%). Which is the better fit depends on your goals.
| NE | REGN | |
|---|---|---|
Market Cap | $6.51B | $83.19B |
Sector | Technology | Health |
52-Week High | $54.37 | $812.27 |
52-Week Low | $26.61 | $555.51 |
Enterprise Value | $7.94B | $77.90B |
Dividend Yield | 4.91% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.77, up 0.2% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $0.01 per share, missing estimates, while revenue declined to $3.1B in 2026 from $3.3B in 2025. Recent news includes a fraud investigation announcement and new drilling contracts, creating investor uncertainty amid operational challenges.
The outlook remains cautious with analyst consensus at Buy (31%) and a $46 price target offering 13% upside. Key risks include earnings volatility, legal scrutiny, and competitive pressures in offshore drilling. Positive cash flow and dividend payments provide some stability, but execution on new contracts and margin improvement are critical for sustained growth.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
